Bacillus calmete-guérin plus interferon-α2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity

Jemal, 2002, Cancer Statistics, 2002, CA Cancer J Clin, 52, 23, 10.3322/canjclin.52.1.23

Messing, 1998, Urothelial tumors of the urinary tract, 2327

Dalbagni, 2000, Current use and questions concerning intravesical bladder cancer group for superficial bladder cancer, Urol Clin North Am, 27, 137, 10.1016/S0094-0143(05)70241-X

Herr, 2000, Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors, J Urol, 163, 60, 10.1016/S0022-5347(05)67972-4

Herr, 1995, Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer, J Clin Oncol, 13, 1404, 10.1200/JCO.1995.13.6.1404

Nseyo, 1996, Therapy of superficial bladder cancer, Semin Oncol, 23, 598

Morales, 1981, Treatment of residual noninfiltrating bladder cancer with bacillus Calmette-Guerin, J Urol, 125, 649, 10.1016/S0022-5347(17)55150-2

Lamm, 1991, A randomized trial of intravesical doxorubicin and immunotherapy with bacillus Calmette-Guerin for transitional cell carcinoma of the bladder, N Engl J Med, 325, 1205, 10.1056/NEJM199110243251703

Herr, 1986, Long term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder, J Urol, 135, 265, 10.1016/S0022-5347(17)45604-7

Lamm, 1992, Long-term results of intravesical therapy for superficial bladder cancer, Urol Clin North Am, 19, 573, 10.1016/S0094-0143(21)00424-9

Vegt, 1995, A randomized study of intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder, J Urol, 153, 929, 10.1016/S0022-5347(01)67606-7

Lamm, 1992, Carcinoma in situ, Urol Clin North Am, 19, 499

Lamm, 1992, Complications of bacillus Calmette-Guerin immunotherapy, Urol Clin North Am, 19, 565, 10.1016/S0094-0143(21)00423-7

Glashan, 1990, A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder, J Urol, 144, 658, 10.1016/S0022-5347(17)39547-2

Belldegrun, 1998, Superficial bladder cancer, J Urol, 159, 1793, 10.1016/S0022-5347(01)63160-4

Williams, 1996, Pilot study of intravesical alfa-2b interferon for treatment of bladder carcinoma in situ following BCG failure, J Urol, 155, 494A

Stricker, 1996, Bacillus Calmette-Guerin plus intravesical interferon alpha-2b in patients with superficial bladder cancer, Urology, 48, 957, 10.1016/S0090-4295(96)00375-5

Bercovich, 1995, BCG vs. BCG plus recombinant alpha-interferon 2b in superficial tumors of the bladder, Arch Ital Urol Androl, 67, 257

O’Donnell, 2001, Salvage intravesical therapy with interferon-α2B plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed, J Urol, 166, 1300, 10.1016/S0022-5347(05)65757-6

Esuvaranthan, 2000, A phase IIB trial of BCG combined with interferon alpha for bladder cancer, J Urol, 163, 152A

Pagano, 1995, Improving the efficacy of BCG immunotherapy by dose reduction, Eur Urol, 27, 19, 10.1159/000475204

Lamm, 2000, Maintenance BCG immunotherapy in recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma, J Urol, 163, 1124, 10.1016/S0022-5347(05)67707-5

Nadler, 1994, Durability of the tumor-free response for intravesical bacillus Calmette-Guerin therapy, J Urol, 152, 367, 10.1016/S0022-5347(17)32741-6

Martinez-Pineiro, 1995, Improving the safety of BCG immunotherapy by dose reduction. Cooperative Group CUETO, Eur Urol, 27, 13, 10.1159/000475203

Morales, 1992, Dose-response of bacillus Calmette-Guerin in the treatment of superficial bladder cancer, J Urol, 147, 1256, 10.1016/S0022-5347(17)37532-8

Mack, 1995, Five-year results of a phase II study with low-dose BCG therapy in high-risk superficial bladder cancer, Urology, 45, 958, 10.1016/S0090-4295(99)80115-0

Mack, 2001, The ablative effect of quarter dose bacillus Calmette-Guerin on a papillary marker lesion of the bladder, J Urol, 165, 401, 10.1097/00005392-200102000-00011

Torti, 1988, Alpha-interferon in superficial bladder cancer, J Clin Oncol, 6, 476, 10.1200/JCO.1988.6.3.476

Hoeltl, 1991, How effective is topical alpha-2b interferon in preventing recurrence of superficial bladder cancer?, Brit J Urol, 68, 495, 10.1111/j.1464-410X.1991.tb15393.x

Catalona, 1987, Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer, J Urol, 137, 220, 10.1016/S0022-5347(17)43959-0

Steinberg, 2000, Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder, J Urol, 163, 761, 10.1016/S0022-5347(05)67799-3

Malmstrom, 1999, 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder cancer, J Urol, 161, 1124, 10.1016/S0022-5347(01)61607-0

Luciani, 2001, Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer, Urology, 58, 376, 10.1016/S0090-4295(01)01187-6